glp 1 drink BOOST® PRE-MEAL HUNGER SUPPORT NUTRITIONAL BOOST® PRE-MEAL HUNGER SUPPORT NUTRITIONAL

The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (dulaglutide, exenatide, liraglutide, semaglutide and tirzepatide) has been further updated to highlight the potential risk of severe acute pancreatitis with these products, including rare reports of necrotising and fatal pancreatitis

Millions of Americans have turned to cheaper, compounded versions of Ozempic and Wegovy

The year delivered progress across clinical evidence, policy, and changing market dimensions, reinforcing obesity as a chronic disease requiring structured, long-term management

Learn how standard titration and microdosing compare and why a licensed provider should guide your dosing plan.

The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.